<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934725</url>
  </required_header>
  <id_info>
    <org_study_id>SECRETO</org_study_id>
    <nct_id>NCT01934725</nct_id>
  </id_info>
  <brief_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome</brief_title>
  <acronym>SECRETO</acronym>
  <official_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SECRETO Study Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SECRETO Study Consortium</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes
      occur at younger ages. Stroke at young age causes marked disability at worst and thus
      long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature
      death compared with background population. Up to 60% of young patients with ischemic stroke
      remain without definitive etiology for their disease despite extensive modern diagnostic
      work-up. This is called a 'cryptogenic stroke'. The group of cryptogenic strokes includes
      those with patent foramen ovale (PFO) or other abnormalities in the atrial septum in the
      heart as the only or concomitant finding. Population prevalence of PFO is high, 25%, and the
      mechanisms how PFO would be associated causally with ischemic stroke remain to be clarified.
      Moreover, there are only scarce data on clinical outcome, long-term risk of new vascular
      events, and prevention of such events in these patients.

      DESIGN: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the
      Etiology, Triggers, and Outcome (SECRETO) is an international prospective multicenter
      case-control study of young adults (age 18-49) presenting with an imaging-positive
      first-ever ischemic stroke of undetermined etiology (aim N=2000). Patients are included
      after standardized diagnostic procedures (brain MRI, imaging of intracranial and
      extracranial vessels, cardiac imaging, and screening for coagulopathies) and age- and
      sex-matched to healthy controls in a 1:1 fashion. Up to 45 study sites worldwide will be
      needed to recruit the planned participant population during a 3-year period. Neurovascular
      imaging and echocardiography studies, and ECGs will be read centrally.

      AIMS: SECRETO involves five principal fields of investigation: (1) Stroke triggers and
      clinical risk factors; (2) Long-term prognosis (new vascular events, functional and
      psychosocial outcomes); (3) Abnormalities of thrombosis and hemostasis; (4) Biomarkers of
      e.g. inflammation, atherogenesis, endothelial function, thrombosis, platelet activation, and
      hemodynamic stress to characterize postulated cryptogenic stroke mechanisms; and (5) genetic
      study, including genome-wide association and candidate gene studies as well as
      next-generation sequencing approach. All analyses consider cardiac functional and
      interatrial structural properties as a possible mediator. Furthermore, SECRETO Family Study
      (substudy) aims at collecting extensive family history of thrombotic events from informative
      patients being screened for SECRETO main study and collect genetic samples from all
      consenting family members for whole-genome sequencing.

      SIGNIFICANCE: SECRETO will provide novel information on clinical and subclinical risk
      factors, both transient and chronic, predisposing to cryptogenic ischemic stroke in young
      adults. This study also reveals long-term prognosis of this understudied patient population
      and may discover new genetic background underlying the disease mechanism and provide
      potential targets for drug development.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Nonfatal or fatal recurrent ischemic stroke</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of noncerebrovascular arterial or venous thrombotic events, or cerebral venous thrombosis</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional outcome will be assessed with modified Rankin Scale at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vocational outcome</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vocational status will be assessed at each follow-up contact with Poststroke Working Activity Questionnaire and a set of questions designed for the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Social outcome</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Social status will be assessed at each follow-up contact with Oslo Social Support Scale and set of questions designed for the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive outcome</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognition will be assessed at mandatory 3-month follow-up visit (Montreal Cognitive Assessment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Poststroke anxiety and depression will be evaluated at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with Hospital Anxiety and Depression Scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life will be assessed at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with EuroQol questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Caregiver burden</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Poststroke burden to caregiver will be assessed at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with Expanded Caregiver Strain Index Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Barthel Index</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional outcome will be assessed with Barthel Index at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Brain Infarction</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Thrombosis</condition>
  <condition>Foramen Ovale, Patent</condition>
  <arm_group>
    <arm_group_label>Patients w/ cryptogenic ischemic stroke</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stroke-free control subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients at baseline:

      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300
      µL cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube
      #2, full blood for DNA extraction.

      Patients at 3-month visit (fasting): 4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300
      µL cryovials; 1 x 5 mL PPACK sodium citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8
      mL serum tube, aliquoted in 5 x 300 µL cryovials; 1 x 9 mL EDTA tube, aliquoted in 10 x 300
      µL cryovials.

      Control subjects:

      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300
      µL cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube
      #2, full blood for DNA extraction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients aged 18 to 49 hospitalized due to first-ever imaging-positive ischemic
             stroke of undetermined etiology;

          2. Age-, gender- and race-ethnicity-matched stroke-free control subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        PATIENTS:

        Inclusion Criteria:

          1. Age 18 to 49 at stroke onset

          2. Patient hospitalized due to first-ever imaging-positive ischemic stroke of
             undetermined etiology after complete timely diagnostic testing.

        Exclusion Criteria:

          1. Baseline mandatory tests not obtained in the first week following stroke onset,
             including:

               -  Brain MRI

               -  Routine blood tests, including complete blood count with differential, CRP,
                  fasting glucose, creatinine, aPTT, INR, total cholesterol, LDL-cholesterol,
                  HDL-cholesterol, HbA1C,hemoglobin electrophoresis in individuals of African
                  origin

          2. Other baseline mandatory tests not obtained within the first two weeks following
             stroke onset, including:

               -  Imaging of cervicocephalic arteries by CTA, MRA, or catheter angiography

               -  Transesophageal (highly recommended) or transthoracic echocardiography

               -  24-hour Holter monitoring

               -  Screening for thrombophilia, including antiphospholipid antibodies and other
                  coagulopathies (any abnormal finding must be retested at mandatory 3-month
                  follow-up visit &gt;12 weeks from initial testing or &gt;4 weeks after cessation of
                  anticoagulation at any later time point); mandatory tests include
                  anticardiolipin antibodies, lupus anticoagulant, anti-β2-glycoprotein
                  antibodies, factor V mutation (or aPC resistency ruled out), factor II mutation,
                  homocysteine, antithrombin III, protein C, and protein S

          3. No evidence of current brain ischemia

          4. Current stroke due to cerebral venous thrombosis or as a complication of subarachnoid
             hemorrhage, angiography, or cardiac surgery

          5. Patient otherwise not eligible for the study or adherent for follow-up (eg
             nonresident) or has concurrent disease affecting outcome (eg. multiple sclerosis,
             cancer)

          6. Informed consent not obtained from the patient or a proxy.

        CONTROL SUBJECTS:

        Inclusion Criteria:

          1. Age 18 to 49 years

          2. Absence of prior ischemic stroke as ascertained using the Questionnaire for Verifying
             Stroke-Free Status

        Exclusion Criterion:

        1.  Informed consent not obtained
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain Lanthier, MD, OD, CSPQ</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM - Hôpital Notre-Dame</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kittner, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
    <phone>+35894711</phone>
    <email>jukka.putaala@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Turgut Tatlisumak, MD, PhD</last_name>
    <phone>+35894711</phone>
    <email>turgut.tatlisumak@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aneesh Singhal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aneesh Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franz Fazekas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franz Fazekas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Enzinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Gattringer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Thijs, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Thijs, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Lanthier, MD, OD, CSPQ</last_name>
    </contact>
    <investigator>
      <last_name>Céline Odier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain Lanthier, MD, OD, CSPQ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <phone>+35894711</phone>
      <email>jukka.putaala@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Turgut Tatlisumak, MD, PhD</last_name>
      <phone>+3584711</phone>
      <email>turgut.tatlisumak@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Sami Curtze, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Strbian, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Gordin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mika Lehto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Sinisalo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauri Soinne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiina Sairanen, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terttu Heikinheimo-Connell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satu Mustanoja, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markku Kupari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per-Henrik Groop, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Haapaniemi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Turgut Tatlisumak, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>F-59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Leys, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Didier Leys, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Lucas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Bodenant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis Mas, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Louis Mas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loubna Majhadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Calvet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Larrue, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Larrue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanislav Christian, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Tanislav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen a. Rh.</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armin J Grau, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Armin J Grau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederik Palm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Pezzini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Pezzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank-Erik de Leeuw, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Frank-Erik de Leeuw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Halvor Naess, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Halvor Naess, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Waje-Andreassen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José M. Ferro, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>José M. Ferro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Geraldes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Engelter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Engelter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Gensicke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian D. Seiffge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nils Peters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 7, 2013</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SECRETO Study Consortium</investigator_affiliation>
    <investigator_full_name>Jukka Putaala</investigator_full_name>
    <investigator_title>Associate Prof., MD, PhD, MSc</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>Stroke in the Young</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Cerebral Venous Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Databases, Genetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
